Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LifeStem's autologous stem cell therapy is an experimental regenerative medicine approach designed to treat non-obstructive azoospermia, a condition where sperm production is severely impaired or absent. The therapy involves the extraction of adult stem cells from the patient's own bone marrow, which are then processed and delivered via direct testicular injection into the seminiferous tubules or interstitial spaces. The primary objective is to restore spermatogenesis by allowing the transplanted autologous stem cells to differentiate into functional germ cells within the testicular microenvironment. This treatment aims to address male infertility by leveraging the regenerative potential of bone marrow-derived stem cells to repopulate the germ cell niche and potentially restore fertility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow-derived stem cells (LifeStem).